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INTRODUCTION 
Markers are sought to detect conditions or predict future onset of conditions. Examples 
include childhood screening tests, tests for genetic abnormalities, and markers for cardiovascular 
disease such as serum lipids and inflammatory indicators. Biomarkers for cancer detection 
include prostate specific antigen and CA-125.  Some of these same markers are used as markers 
of treatment response and of disease progression. The emergence of new technologies such as 
gene and protein expression arrays promise the development of more sophisticated markers in 
the near future.1,2  
The issue here is how to evaluate the performance of a marker. The importance of 
rigorously evaluating a marker’s performance before it is adopted in routine medical practice is 
of particular concern to regulatory agencies and has recently been highlighted in the popular 
press.3 The ultimate validation of a marker requires large population studies and consideration of 
disease-specific costs and benefits associated with incorrect and correct classification by the 
marker.4 Preliminary to such studies are smaller studies that simply assess the marker’s ability to 
discriminate subjects with the condition from those without. The statistical evaluation of a 
marker’s discriminatory capacity is the specific topic we discuss in this paper. 
How should one measure the discriminatory capacity of a marker? An appropriate 
measure should not depend on the measurement units of the marker. If it does, it cannot be used 
to compare markers measured in different units. For example, the odds ratio (or relative risk) per 
unit increase in the marker, although commonly used, is not a self-contained summary statistic of 
discrimination and cannot be compared across different markers.6  
We propose an approach that first involves standardizing the marker values relative to a 
normative population (those without the condition). This standardization puts different markers 
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on a common scale, thereby facilitating comparisons amongst markers. In addition we show that 
the distribution of the standardized marker among subjects with the condition is closely related to 
the receiver operating characteristic (ROC) curve, a statistical tool that has long been used for 
evaluating diagnostic tests. 7—9 The ROC curve is appropriate for evaluating the discriminatory 
capacity of any marker.10 Its interpretation as relating to the distribution of standardized marker 
values is appealing. In particular it may be of interest to those researchers already comfortable 
with statistical concepts of standardization and frequency distributions, but who are not familiar 
with ROC analysis. 
METHODS 
Datasets 
To illustrate concepts we apply statistical techniques to two simple datasets. The data are 
online at http://www.fhcrc.org/labs/pepe/book/. In the first, two serum biomarkers for pancreatic 
cancer, CA-125 and CA19-9, were measured for 90 patients with pancreatic cancer and 51 
without11 (Figure 1).  Questions of interest are: (i) how to quantify the capacities of the two 
markers to distinguish between the patients with and without cancer; and (ii) to compare the two 
markers.  
The second dataset pertains to a marker of hearing impairment at the 1416 Hz freqeuncy  
for  57 hearing impaired ears  and 147 unimpaired ears. The marker is the signal-to-noise ratio 
(SNR) from the distortion product otoacoustic emissions (DPOAE) test. The test was performed 
using 9 different sound stimulus intensity levels, 3 of which are included in this dataset. Thus for 
each ear we have an SNR value for each of the intensity levels (Figure 2). Details of the original 
study and data selection can be found in Stover et al12 and in Pepe,13 respectively.  
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Both of these studies employed case-control designs. Cross-sectional cohort studies can 
be analysed in the same way. 
Approach 
To explain the general approach we adopt the convention that higher values of the marker 
are more indicative of the presence of the condition. (We can always redefine the marker if 
necessary to ensure this, using negation for example. See the audiology data in Figure 2.) The 
basic idea is to use the distribution of marker values in the unaffected population, without the 
condition, as a reference distribution for standardizing marker values in the affected population, 
i.e., those with the condition. The standardization for an affected subject with marker value Y is 
simply to calculate the frequency of unaffected subjects with marker values greater than Y. Thus 
if marker values for 20% of unaffected subjects exceed Y, the standardized marker value is 0.20. 
We call the standardized value its placement value.14—16 
The concept of calculating a placement value is closely related to that of calculating a 
percentile value relative to a healthy reference population as is the common practice for reporting 
anthropometric measurements in children.17  Here, rather than reporting the percentile, the 
proportion of the reference population less than Y, we report the proportion greater than Y. 
Although the concepts are equivalent, we will see that calculation of placement values rather 
than percentiles facilitates connections with ROC methodology.  
Placement values are proportions taking values between 0 and 1. Since higher marker 
values are more indicative of  the condition,  having the condition is associated with having 
smaller placement values. The smallness of the placement value indicates how extreme a 
subject’s marker value is relative to the reference population. Moreover, a marker for which most 
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affected subjects have very small placement values is a good marker because it identifies most 
affected subjects as being extreme relative to the reference population.  
A key attribute of placement values is that they do not have measurement units associated 
with them. Different markers are converted to a common scale by the placement value 
standardization. This facilitates comparisons amongst them. Thus if a diseased subject has a 
placement value of .50 for marker 1 and placement value .01 for marker 2, then marker 2 is the 
better disease indicator for him. He is identified as extreme in regards to marker 2 while he 
appears to be well within the reference (non-diseased) population in regards to marker 1. To 
determine which of two markers is better at discriminating the population of affected subjects 
from the unaffected population, one must consider the population distributions of placement 
values in affected subjects for each of the markers. The marker with a higher frequency of small 
placement values is preferred. 
ROC Curve 
The ROC curve is a statistical device for illustrating the classification accuracy 
achievable with a diagnostic test, or marker.9,10,16 For each possible threshold value, c, one can 
define a positive classification rule based on the marker, cY ≥  indicating that the condition is 
present. The associated true positive rate (TPR(c)) and false positive rate (FPR(c)) are 
TPR )(c  = proportion of affected subjects with cY ≥  
and 
FPR )(c  = proportion of unaffected subjects with cY ≥ , 
respectively. The ROC curve plots TPR )(c , the test sensitivity, versus FPR )(c , 1-specificity, for 
all values of c. It shows the range of (FPR, TPR) achievable. Since good classification accuracy 
pertains to low FPRs and high TPRs, a good marker has an ROC curve with points in the upper 
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left corner of the )1,0()1,0( ×  square. The area under the ROC curve (AUC) is the most popular 
ROC summary statistic. An AUC of 1.0 corresponds to a perfect marker. 
RESULTS 
Pancreatic Cancer Biomarkers 
Using the 51 subjects without pancreatic cancer as the reference group we standardized 
each of the markers for the 90 subjects with pancreatic cancer by calculating placement values. 
The frequency distributions are displayed in Figure 3a.  The CA-19-9 placement values are 
smaller than the CA-125 values indicating that pancreatic cancer patients  are more extreme 
relative to the non-cancer reference in regards to CA19-9 than in regards to CA-125 
The average (sd) of the placement values is .14 (.26) for CA 19-9 and .29 (.25) for CA-
125. A simple paired t-test could be applied to compare the averages. However it is not quite 
appropriate because a finite sample of only 51 non-cancer patients was used to standardize the 
markers. A different sample of non-cancer patients would have produced a somewhat different 
standardization. The sampling variability in the reference group used to calculate the placement 
values for the 90 diseased subjects must be accounted for in calculating a p-value that compares 
mean CA-19-9 and CA-125 placement values. The bootstrapping technique18 described in the 
electronic appendix does this and yields p < .01.  
The scatterplot (Figure 3(b)) shows that although CA19-9 is the better marker overall, 
there are a substantial number of cancer patients for whom CA-125 is better in the sense that 
they are normal in regards to CA19-9 but abnormal in regards to CA-125. For example, 5 
patients with CA-19-9 placement values exceeding 20% had CA-125 values less than 10%. 
Audiology Testing 
Hosted by The Berkeley Electronic Press
  6
Distributions of standardized –SNR values (negative SNR) are shown in Figure 4 for 
hearing impaired subjects. It appears that the test is more discriminatory when the sound 
stimulus is at a lower intensity since the placement values are smaller at the 55dB intensity level 
versus at the 60 and 65 dB levels. The average (sd) values are .029 (.057), .053 (.106), and .071 
(.127), respectively.  The p-value for comparing the averages at  55 and 65dB  is < .01 using the 
bootstrap technique.  Interestingly the 55 dB stimulus appears to work better than the 65dB 
stimulus for most individuals as can be seen from the scatterplot in Figure 4 (b). That is, the test 
results for most hearing impaired subjects appeared more abnormal with the lower intensity 
stimulus, as evidenced by smaller placement values. 
Relationship with ROC analysis 
Figures 3(c) and 4(c) show the cumulative distributions (cdf) of standardized markers for 
cancer patients and for hearing impaired subjects respectively. The cdf corresponding to p on the 
x-axis is the proportion of values that are ≤ p. Interestingly these cumulative distribution curves 
are identical to ROC curves for the markers. The general argument is as follows: Let c be the 
threshold value that corresponds to the false-positive rate p, FPR pc =)( . Consider the point 
cdf(p) on the cumulative distribution curve. Observe that a subject’s placement value is ≤p if and 
only if his marker value Y ≥c. Therefore the proportion of affected subjects with placement 
values ≤p, namely cdf(p), is equal to the proportion with marker values ≥c, i.e., TPR )(c . So, 
each point (p, cdf(p)) on the cumulative distribution curve is a point (FPR(c), TPR(c)) on the  
ROC curve and vice versa. A mathematical argument is given in Pepe and Cai.15  
There are two interpretations then for the curves shown in Figures 3(c) and 4(c). 
Interpreted as cumulative distribution functions, we see the proportion of affected subjects with 
standardized marker values as or more extreme than p. Interpreted as ROC curves we see the 
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trade-offs between sensitivity and specificity that are possible when we apply thresholding 
classification rules to the marker in the population. Both interpretations are meaningful and 
useful. The accuracy of CA19-9 for classifying subjects with or without pancreatic cancer is 
clearly superior to CA-125. For example, the thresholding rule with specificity of 80% 
(FPR=.20) yields a sensitivity of 78% for CA19-9 but only 49% for CA-125. Said another way, 
78% of cancer patients have standardized CA-19-9 below 0.2 while only 49% have standardized 
CA-125 below 0.2. Similarly we see from Figure 4 (c) that classification accuracy is better when 
the lower sound intensity  is employed. 
ROC Summary Statistics 
The areas under the ROC curves in Figure 3(c) are .86 for CA 19-9 and .71 for CA-125.  
Those in Figure 4(c) yield AUCs of .97 at 55 dB, .95 at 60 dB, and .93 at 65 dB. Observe that 
these are exactly the same as 1 minus the mean placement values calculated earlier. The result 
holds in general that averaging standardizing markers for affected subjects yields 1–AUC. 
average (placement value)=1–AUC. 
It is intuitive for the perfect marker since all placement values for affected subjects are equal to 0 
and AUC = 1 for the perfect marker. Mathematical arguments for the general result are 
available.14,15 
The implication of this result is that statistical comparisons between markers using areas 
under ROC curves are the same as statistical comparisons between markers using placement 
value averages for diseased subjects. Therefore the p-values cited earlier that pertain to average 
placement values are also valid for comparing the AUCs in Figures 3(c) and 4(c). 
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DISCUSSION 
The main contribution of this paper is to suggest a standardization procedure to facilitate 
the evaluation of markers. Use of a reference distribution is a familiar concept. In laboratory 
medicine for example values outside of a normal healthy reference range often flag patients as 
having a medical condition. Standardization with respect to an age and gender matched reference 
population is used for anthropometric measurements. Standardization not only  provides better 
clinical interpretations but  makes possible valid comparisons of different populations. Our 
standardization can  be used to compare a marker's discriminatory capacity across different 
populations.  One could compare placement values in diseased men and diseased women, for 
example, to determine if the marker performs better in men or women. An additional compelling 
attribute of the standardization we propose is that it makes possible valid comparisons of 
different markers across the same population, as demonstrated with our two datasets.  
We also noted the close connection between analysing standardized markers of affected 
subjects and ROC analysis. With our approach one can analyze standardized markers in familiar 
ways, as we did for pancreatic cancer and hearing impairment markers, without explicitly 
considering operating characteristics of thresholding decision rules. Nevertheless we have shown 
that such considerations are implicitly at play and the approach is fundamentally the same as 
ROC analysis. 
Our approach offers avenues for addressing questions that should be, but are typically not 
asked about marker performance. In particular, regression analysis applied to placement values 
can be used to determine if covariates affect the capacity of a marker to distinguish cases from 
controls.15,19 Covariates may relate to characteristics of subjects tested or to the test itself. 16  To 
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illustrate with the audiology data, the following linear regression model was fit to the placement 
values for hearing impaired subjects:  
Z = Z (placement value) = 10 αα +  Intensity ε+  
with Z, the normal deviate corresponding to the placement value, and covariate, Intensity, being 
the sound stimulus intensity. The estimate =1α  0.023 (95% confidence interval =(-.019, .076); 
se=.024) indicates a trend for higher intensity levels being associated with larger placement 
values among hearing impaired subjects, i.e., reduced marker performance. Figure 4c shows the 
corresponding cumulative distributions of placement values. The more frequent occurrence of 
small placement values at the lower intensity levels is obvious from these curves. The better 
performance at lower intensity is also evident with the ROC curve interpretation. More complex 
models that include multiple independent variables simultaneously can easily be fit too. As noted 
earlier,  bootstrapping is applied to arrive at appropriate standard errors and p-values. 
Alternatively, recent work15,19 provides theory for making statistical inference about regression 
models using placement values. 
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Appendix: Testing for a difference in the mean Placement Value between two disease markers:  
Bootstrap estimation of the achieved significance level. 
 
With paired observations on the two markers, A and B, the test statistic is the average 
placement value difference between markers,  
( )∑ −=
i
A
i
B
i WWn
1θˆ , 
where n = number of cases, and  W i  is the placement value of the marker for case i and the 
superscript indicates the marker. The null hypothesis to be tested is 0 : 0H θ = . The sampling 
variability of placement values calculated for disease cases depends not only on marker 
variability among the cases but also among the controls used to estimate the reference 
distribution.   
 
In order to approximate the null distribution of θˆ  and estimate the achieved significance 
level, we sampled from the empirical distribution of θˆ  and centered the distribution at zero, the 
desired null mean.   Specifically, samples of paired marker observations, equal in size to the 
original case and control samples, were drawn separately, with replacement, from the observed 
case and control samples.  The test statistic, kθˆ , was calculated for each set of case and control 
“bootstrap” samples, k = 1, ... 1000, and translated to conform to the null distribution by 
subtracting the original obsθˆ  from the bootstrap sample, obskk θθθ ˆˆˆ −=∗ . The achieved 
significance level of the test was then calculated as the proportion of the bootstrap ∗kθˆ ’s more 
extreme than the observed obsθˆ , i.e. obsk θθ ˆˆ ≥∗ . 
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FIGURE LEGENDS 
Figure 1. Distributions of pancreatic cancer biomarkers in 51 subjects with pancreatic 
cancer and 90 subjects without cancer. 
Figure 2. Distributions of –SNR values from the DPOAE test in 57 ears with hearing 
impairment and in 147 ears without impairment at the 1416 HZ frequency. The test was 
applied using input stimulus of intensities 55 dB, 60 dB and 65 dB. Shown are –SNR values 
(rather than SNR values) to agree with the convention of higher marker values being more 
indicative of hearing impairment. 
Figure 3. Distributions of standardized biomarkers (placement values) in 90 subjects 
with pancreatic cancer. Shown are (a) frequency distributions (b) scatter plots and (c) 
cumulative distributions . 
Figure 4. Distributions of placement value standardized –SNR in 57 hearing impaired 
ears at 3 stimulus intensity levels (55 dB, 60 dB, and 65 dB). Shown are (a) frequency 
distributions, (b) scatter plots and (c) cumulative distributions . 
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